COLUMBIA, Mo. -- Low-density lipoproteins (LDL) — commonly known as bad cholesterol — have long been on scientists’ radar as a major contributor to heart disease.

PCSK9 enhances LDL cholesterol (LDL-c) levels by escorting the liver LDL receptor (LDLR) to endosomes and lysosomes for degradation. PCSK9 monoclonal antibodies and RNA-antisense formulations are ...